GIST


Also found in: Dictionary, Thesaurus, Legal, Acronyms, Idioms, Encyclopedia, Wikipedia.
Gastrointestinal Stromal Tumour. A relatively uncommon mesenchymal tumour of the gastrointestinal tract; two-thirds arise in the stomach, nearly one-third in the small intestine and less than 10% elsewhere. They are often incidental findings at endoscopy—especially in Japan due to mass screening for gastric cancer—or at surgery for other causes
Epidemiology More common in the middle-aged to elderly
DiffDx Leiomyoma, schwannoma, sarcoma, adenocarcionoma, ectopic pancreas
Management Most GISTs respond well to the tyrosine-kinase inhibitor imatinib mesylate (Gleevec/STI-571)
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

GIST

Gastrointestinal stromal tumor, see there.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

GIST

gastrointestinal stromal tumor.
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
Jason Yang noted: 'Early symptoms of GIST are relatively unpronounced; as a result, some GIST patients are undiagnosed until advanced stages.
mutations in exons 12, 14 and 18, including the exon 18 D842V mutation, involved in a subset of GIST.
- The majority of the industry-sponsored drugs in active clinical development for GIST are in Phase II.
The fact that the genotype of each GIST influences the treatment response, drug resistance, and prognosis, accurate diagnosis is essential for adequate and prompt treatment.
Apoptosis of GIST cells was detected using annexin V-FITC Apoptosis Detection kit (Abcam, USA) according to the manufacturer's protocol.
Gastrointestinal Stromal Tumors (GIST): a prospective analysis and an update on biomarkers and current treatment concepts.
Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies.
In certain reports, rectal GIST is classified into two risk groups where low-risk group refers to tumors smaller than 5 cm and exhibiting fewer than 5 mitoses per 50 HPF and the high-risk group includes patients with tumors of 5 cm and more or exhibiting more than 5 mitoses per 50 HPF or both.[25],[28] Hohenberger and Eisenberg additionally concluded that low-risk GIST may not benefit from adjuvant treatment if resected with clear margins; however, for high-risk lesions, adjuvant therapy must be considered.[28]
ORs and associated 95% CIs were used to assess the treatment efficacy of sunitinib in imatinib-resistant or imatinib-intolerant GIST patients with different genotypes.
Most case reports present cases of diagnosed GIST with subsequent development of Desmoid tumor.
Based on tumor size and mitotic activity, possibility of a malignant GIST was suggested along with immunohistochemical analysis (CD117 and CD34) for further confirmation.